If you are over 40 and stuck, you are not imagining it
A version of this conversation happens almost every week in my practice. A woman in her mid-forties walks in frustrated. The diet that worked at 32 is not working. The workouts that kept her at her old weight are barely holding it now. The scale has crept up six, twelve, sometimes twenty pounds — mostly around the middle — despite no change in effort.
She apologizes. She thinks something is wrong with her motivation. It is not. Her biology has shifted, and the strategies that worked at 30 are now fighting an uphill metabolic, hormonal, and neurochemical battle that none of us were taught about in school.
What follows is, in order, the nine real physiological reasons perimenopause weight gain is harder — each one a documented mechanism with real research behind it — and then what the Mayo Clinic's January 2026 study on tirzepatide combined with menopausal hormone therapy actually showed about a combination that may meaningfully change the equation.
The 9 reasons perimenopause weight gain is harder
In premenopausal women, estrogen helps direct fat storage toward the hips and thighs — a metabolically safer pattern. As estrogen levels fall in perimenopause and after menopause, fat redistributes toward the abdomen. The waist gets thicker even when total weight has not changed much, and the new fat is visceral: deeper, surrounding internal organs, and metabolically more dangerous. Average waist circumference rises by approximately 5 to 10 cm across the menopausal transition.
Resting metabolism — the calories your body burns simply existing — declines during midlife. Estimates from recent metabolic research put the drop at roughly 100 to 200 calories per day. That sounds small. Over a year, at 150 calories per day, it is the equivalent of roughly 15 pounds of stored energy — the exact "I gained 15 pounds and I don't know how" pattern most women describe.
Sarcopenia — the gradual loss of lean muscle mass — accelerates after 40. Muscle is the most metabolically active tissue in the body. Less muscle means a lower baseline metabolic rate, which compounds the decline in #2. Without active resistance training and adequate protein intake, women typically lose 3 to 5 percent of muscle mass per decade after 30 — and this loss accelerates in the perimenopausal years.
Estrogen helps the body respond efficiently to insulin. As estrogen declines, insulin sensitivity often falls, meaning your body needs to produce more insulin to handle the same amount of carbohydrate. Higher circulating insulin promotes fat storage and makes fat loss harder. This is part of why women in perimenopause often describe sudden carbohydrate intolerance: the same meals that used to be fine now feel like they go straight to the waist.
Hot flashes, night sweats, and shifting hormone levels routinely disrupt deep sleep in perimenopause. Poor sleep elevates cortisol, drives next-day cravings — especially for sugar and refined carbohydrates — and impairs glucose tolerance. The cycle compounds: bad sleep increases hunger hormones, increased hunger drives poor food choices, and poor food choices further degrade sleep.
Leptin (the satiety hormone) and ghrelin (the hunger hormone) shift their balance during menopause. Women often genuinely feel hungrier and less full after the same meal that used to satisfy them. This is one of the most under-discussed shifts of midlife: appetite is biologically altered, not just perceived as harder to manage.
Visceral fat (see #1) is hormonally active. It secretes inflammatory cytokines that drive chronic low-grade inflammation throughout the body. Inflammation impairs insulin signaling, accelerates muscle loss, and creates a metabolic environment that resists fat loss. The more visceral fat accumulates, the more inflammation rises — a self-reinforcing loop.
Postmenopausal women face rising rates of type 2 diabetes, cardiovascular disease, fatty liver disease, and hypertension — all driven in part by the changes in #1 through #7. Weight gain in this period is not cosmetic; it is a meaningful health risk. According to Mayo Clinic data, nearly 68 percent of women aged 40 to 59 in the United States are classified as overweight or obese, with rates climbing further postmenopause.
Cutting 300 calories per day and adding a few extra cardio sessions per week used to produce predictable weight loss. After 40, with a lower metabolic rate, less muscle mass, shifted appetite signals, and worse sleep, the same "small adjustment" delivers a fraction of the result — or none at all. This is not a moral failing. It is what the biology does. The interventions need to change. Resistance training, protein-forward eating, sleep prioritization, and stress management all matter more after 40 than they did before.
What the new Mayo Clinic study actually showed
Against this backdrop of biological headwinds, a Mayo Clinic-led research team — with senior authors including Dr. Maria Daniela Hurtado Andrade and Dr. Diego Castaneda — published a retrospective observational study in The Lancet Obstetrics, Gynaecology, & Women's Health on January 22, 2026. The research community has been actively discussing it ever since, with coverage continuing through May and June from Maven Clinic, Veja (Brazil), academic-publication channels, and others.
The question they asked is simple. In postmenopausal women already prescribed tirzepatide for overweight or obesity, did women who were also using menopausal hormone therapy (MHT, also called HRT) lose more weight than women on tirzepatide alone?
The answer, in their cohort:
Retrospective observational analysis. Higher proportions of women in the MHT group also reached ≥20%, ≥25%, and ≥30% body-weight loss milestones. Source: Hurtado Andrade MD, Castaneda D, et al., The Lancet Obstetrics, Gynaecology, & Women's Health, January 22, 2026; 2(2): e118.
That 35% figure is the number going around the news cycle. It is real. It is also worth understanding in context.
In this observational study, women who used menopausal hormone therapy lost about 35 percent more weight than women taking tirzepatide alone. The magnitude of this difference warrants future studies that could help clarify how GLP-1-based obesity medications and menopausal hormone therapy may interact.
Why hormone therapy might amplify a GLP-1 response
Researchers have proposed several plausible mechanisms for this association, none of which are confirmed but all of which fit known biology:
- Estrogen may upregulate GLP-1 receptors in the brain. Preclinical animal studies have shown that estrogen increases the expression of GLP-1 receptors in the hypothalamus — the brain region most involved in appetite regulation. Restoring estrogen via MHT may make the brain more responsive to the appetite-suppressing signals of tirzepatide.
- Estrogen restores a more favorable fat-distribution pattern. By shifting fat storage away from visceral abdominal depots and back toward subcutaneous storage, estrogen may reduce the inflammatory and metabolic resistance described in reasons #1 and #7.
- Better sleep, lower cortisol. For women whose menopausal symptoms include sleep disruption, MHT may indirectly improve weight-loss response by addressing the cascade described in reason #5.
- Preserved muscle. Some data suggest estrogen may slow sarcopenia. More muscle means a higher metabolic rate and a more responsive weight-loss machinery.
These mechanisms are hypothesis, not proof. The Mayo Clinic study identified an association; it did not establish causation.
What this study does NOT mean
This is the part that matters most, especially with the news cycle running hot. The Mayo Clinic finding does not mean:
- It does NOT mean MHT is a weight-loss treatment. Menopausal hormone therapy is not FDA-approved for weight loss. It should not be prescribed for that purpose alone. MHT carries real risks — blood clots, stroke, breast cancer concerns in some patient populations — that have to be weighed individually against benefits for menopausal symptom relief.
- It does NOT mean every postmenopausal woman should add MHT to her tirzepatide. The decision to use MHT is a clinical one, made between a woman and her physician, based on age, time since menopause, personal medical history, family history, and symptom burden. Weight loss is not the indication.
- It does NOT prove causation. The Mayo Clinic study was observational. Women who chose (or were prescribed) MHT may differ from those who did not in ways that affect weight loss independently of the medication — access to care, engagement with their health, lifestyle factors. The authors said this directly.
- It does NOT mean tirzepatide alone is the wrong tool. Tirzepatide-alone patients in this study still lost an average of 14 percent of body weight at 12 months. That is meaningful weight loss. The MHT group lost more on average; the tirzepatide-alone group did not lose poorly.
The critical asterisk for compounded GLP-1 patients
The Mayo Clinic study and every related analysis cited in this article studied patients on FDA-approved tirzepatide — the Eli Lilly brand-name products Mounjaro and Zepbound. Compounded tirzepatide preparations were not included in this research.
Compounded medications are not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. They are prepared by licensed compounding pharmacies under physician supervision. They are not FDA-approved products. No claim about weight-loss outcomes — including the 35 percent additional weight loss observed in the MHT group — should be extrapolated from this study to compounded preparations.
This matters because as this research generates headlines through the summer of 2026, there will be a temptation to imply the same outcomes apply across the entire GLP-1 category. That implication is not supported by the data in this study. For SkinnyVIP patients on compounded tirzepatide: your medication is prescribed for weight management. If you and your physician are evaluating whether MHT is appropriate for your menopausal symptoms, that is a separate clinical conversation — not a tactic for weight loss.
Physician-prescribed compounded tirzepatide for $695 per 3-month plan — about $232/month for any dose. One transparent price. Telemedicine in all 50 states.
Start Your Program →What women 40 to 55 should actually do
Practical guidance, grounded in everything above:
- Stop blaming willpower. Read the nine reasons again. Your biology has shifted. Treat this as a metabolic and hormonal puzzle, not a moral failing.
- Resistance train, twice a week minimum. Of all interventions, preserving and rebuilding muscle has the biggest payoff after 40. It addresses reason #3 directly and ripples into #2, #4, and #9.
- Eat protein-forward. Most physicians recommend at least 1 gram of protein per kilogram of body weight per day for women in this stage of life — many recommend more. This supports muscle preservation and satiety.
- Prioritize sleep. Even one hour of additional consistent sleep can reduce next-day cravings and cortisol. If hot flashes or night sweats are wrecking your sleep, that is a real clinical issue worth raising with your physician.
- Talk to your physician about menopausal symptoms separately from weight. If you have significant menopausal symptoms, a discussion of MHT is appropriate on its own merits — not as a weight-loss tactic. Your doctor will weigh age, time since menopause, history, and risk profile.
- Consider whether a GLP-1 is appropriate for you. If lifestyle interventions alone are not producing results and your overall health profile fits, GLP-1 medications are FDA-approved for weight management and other indications. Your physician decides whether you are a candidate.
- If you are already on a GLP-1 and on MHT, do not change anything based on this single observational study. Keep both treatments as prescribed by the clinicians who put you on them. If you have specific questions about your regimen, ask them.
The bigger picture: a series of "beyond weight loss" findings
This is the sixth significant "GLP-1 does more than weight loss" research story of the last two years. The pattern matters because it tells you something about the trajectory of this drug class:
- March 2024: FDA approved branded Wegovy (semaglutide 2.4mg) for cardiovascular risk reduction in adults with obesity plus established CVD, based on the SELECT trial. SELECT trial breakdown →
- December 2024: FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials.
- January 2025: FDA approved Ozempic (semaglutide 1.0mg) for reducing the risk of kidney failure and cardiovascular death in adults with type 2 diabetes plus CKD, based on the FLOW trial. FLOW trial breakdown →
- End of 2025: Novo Nordisk's Phase III EVOKE/EVOKE+ trial of oral semaglutide in early Alzheimer's failed the primary endpoint — an important reality check.
- January 2026 (this study): Mayo Clinic's tirzepatide-plus-MHT analysis suggests a meaningful synergy in postmenopausal women.
- May 2026 (ASCO 2026): Cleveland Clinic observational data showed 38–50% lower stage-4 cancer-progression rates in GLP-1 users. ASCO 2026 cancer breakdown →
- May 2026 (Washington Post): Brain-imaging research went mainstream — with the EVOKE Alzheimer's trial failure clearly in the picture. WaPo brain story breakdown →
This is what it looks like when a drug class enters medicine seriously and the research community starts asking what else it does. Some signals turn into FDA-approved indications. Others fail in trials. The Mayo Clinic study sits in the early, observational, hypothesis-generating part of that trajectory — meaningful, but not yet definitive.
What to ask your doctor (if you want to have the conversation)
If this article makes you want to bring it up at your next visit, here are the questions worth asking:
- What menopausal symptoms am I experiencing, and is MHT appropriate for my situation on its own merits — separate from any weight conversation?
- Am I a candidate for a GLP-1 medication based on the FDA-approved indications, my BMI, and my health history?
- Given my personal and family history, are there reasons I should or should not consider MHT?
- What specific resistance-training, protein, and sleep targets make sense for me?
- If we ever do start both an MHT regimen and a GLP-1, how will we monitor my response and watch for side effects?
The bottom line
If you are a current SkinnyVIP patient on compounded tirzepatide, this study does not change your plan. If you are considering whether a GLP-1 is right for you, the decision is still based on the conditions GLP-1 medications are FDA-approved for, your individual health profile, and a real consultation with a licensed physician. That is how to do this right.
- Hurtado Andrade MD, Castaneda D, et al. Menopausal hormone therapy combined with tirzepatide in postmenopausal women with overweight or obesity: a retrospective observational cohort study. The Lancet Obstetrics, Gynaecology, & Women's Health. January 22, 2026; 2(2): e118. DOI: 10.1016/S3050-5038(25)00145-1.
- "Women over 50 lost 35% more weight with this surprising combo." ScienceDaily, June 3, 2026. sciencedaily.com
- "How Hormone Replacement Therapy for Weight Loss Helps." Maven Clinic, June 1, 2026. mavenclinic.com
- "O que acontece com o peso quando se combina Mounjaro com a reposição hormonal." Veja, June 1, 2026. veja.abril.com.br
- "Mayo Clinic Tirzepatide MHT Weight Loss Breakthrough." Academic Jobs Higher Education News, May 30, 2026. academicjobs.com
- "The Surprising Hormone That Could Make Menopause Weight Loss Easier." Woman's World / Yahoo Health, June 2, 2026. health.yahoo.com
- Jastreboff AM, et al. Tirzepatide for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.